Cationic Liposome TLR Ligand Mucosal Adhesion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel immunostimulatory compositions that can rapidly and sustainably activate innate immune responses at mucosal surfaces to provide non-specific protection against viral and bacterial infections, as existing compounds often lead to antibiotic resistance and have adverse effects, and few effective immunostimulatory compounds are available for mucosal surfaces.
Innovation Solution
The development of immunostimulatory compositions comprising cationic liposomes, toll-like receptor (TLR) ligands, and cellular adhesion agents, such as carboxymethylcellulose, which are designed to enhance innate immunity by stimulating immune responses at mucosal surfaces, including the nasopharynx, respiratory tract, and reproductive tract, without the need for antibiotics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics or antimicrobial drugs are used to protect against viral and bacterial infections, then protection from infection is achieved, but antibiotic resistance develops and adverse effects occur
Solution Approach 1:
The patent converts the harmful overuse of antibiotics into a beneficial alternative by using immunostimulatory compounds that activate the body's own immune system. Instead of relying on external antimicrobial agents that cause resistance, the invention stimulates innate immune responses (such as cytokine production and immune cell activation) to provide protection against infections without the harmful side effects of antibiotic resistance.
2Reliability
If existing immunostimulatory compounds are used, then some immune activation is achieved, but rapid and sustained activation at mucosal surfaces is insufficient
Solution Approach 1:
The patent applies local quality by specifically designing immunostimulatory compounds that target and activate immune responses at mucosal surfaces (nasopharynx, upper respiratory tract, eye, GI tract, reproductive tract) rather than systemically. The composition includes agents that adhere to mucosal surfaces and locally stimulate innate immunity, creating high concentrations of immune activation precisely where needed for infection protection.
Solution Approach 2:
The patent achieves rapid and sustained immune activation by optimizing parameters of the immunostimulatory composition, including the type of Toll-like receptor ligands used, the formulation vehicle, and the dosage regimen. These parameter changes enable the composition to produce both rapid initial immune responses and sustained activation over time at mucosal surfaces.
3Reliability
If immunostimulatory compositions are introduced to enhance innate immunity, then protection from infection is improved, but the complexity of the composition increases
Solution Approach 1:
The patent achieves universality by creating an immunostimulatory composition that provides broad-spectrum protection against multiple types of pathogens (viruses and bacteria) through a single formulation. The composition contains multiple Toll-like receptor ligands that can recognize different pathogen-associated molecular patterns, allowing one composition to stimulate diverse innate immune responses against various infectious threats without requiring separate treatments for each pathogen type.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compositions effectively induce local, non-specific immune responses, reducing the frequency of infections and enhancing the efficacy of existing vaccines by improving adhesion and immune activation at mucosal surfaces, thereby providing prolonged protection against microbial infections.
Implementation Method 1
immunostimulatory compositions including at least one of (a) cationic liposomes, at least one (b) toll like receptor (TLR) or mixture thereof
Implementation Method 2
cellular adhesion agent... can include, but is not limited to, carboxymethylcellulose (CMC)... improve adhesion and immune activation at mucosal surfaces
Implementation Method 3
toll like receptor (TLR)... ligands... stimulate immune responses at mucosal surfaces
Implementation Method 4
cellular adhesion agent can be a low- to mid-weight viscosity cellular adhesion agent... low- to mid-weight viscosity carboxymethylcellulose
Data Source
AI summary
Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunostimulatory compositions disclosed herein can be directed to preventing or treating an infection, cancer or other immunocompromising health condition in the subject. In some embodiments, the immunostimulatory compositions disclosed herein enhance non-specific immune responses systemically or locally in the subject to treat or reduce the risk of onset of a health condition. In some embodiments, immunostimulatory compositions disclosed can be used to induce a non-specific immune response within mucosal surfaces such as the nasopharynx, upper respiratory tract, eye, GI tract, and reproductive tract to induce a non-specific immune response in order to reduce onset of or treat an infection or other health condition.